The drug development company ISR (Immune System Regulation Holding AB) has signed an agreement with Gerresheimer for large-scale production of the IcoOne nasal inhaler, for its phase III study of its dry powder Covid-19 vaccine.
“They have signed a very important agreement to be able to produce large enough quantities of our game-changing inhaler, to cover the needs of late-stage development studies and pivotal phase III program. This agreement also opens the door for further collaborations with Gerresheimer, to produce sufficient quantities of in- haler to secure our commercial supply chain and the global launch of our exciting dry powder SARS-CoV-2 vaccine,” comments Ola Winqvist, CEO of ISR. “We are happy and delighted to support ISR with our high expertise in the development, industrialization, and manufacturing of drug delivery devices. With our annual production of more than 100 million inhalers we are the ideal partner for ISR,” says Manfred Baumann, Global Executive Vice President of Sales & Marketing, Administration & TCC, Gerresheimer Medical Systems.
ISR is now entering a new phase and securing the long-term partners needed to produce its vaccine for phase III and the market. For the phase III trial, Gerresheimer are now running the design for manufacturing, mold making, and manufacturing the nasal inhaler.
